CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 416 · Search date 2026-07-17 · Methodology v0.6

AB-LIFE probiotic blend,
does it really help with Improved LDL and total cholesterol?

30-Second Summary
C
Evidence Grade C · 57 · Safety caution
A small lipid signal belongs to the three-strain blend, not probiotics in general
What the
research shows
The CECT 7527, 7528, and 7529 blend lowered LDL and total cholesterol in an initial 60-person RCT and a later 86-person RCT. The large initial effect fell to about 3% in the later study, endpoints were lipid surrogates rather than clinical events, and findings belong only to the proprietary strain blend, supporting C with 57 points.
What the
ads claim
Marketing can describe a 'cholesterol probiotic' as though every L. plantarum strain or probiotic shares the effect. The evidence belongs to the 1:1:1 blend of CECT 7527, 7528, and 7529 and does not establish cardiovascular-event prevention or medication replacement.
*

Useful facts when choosing a product

  • The Korean individually recognized ingredient number is 2022-14, with an intake of AB-LIFE at 1.2×10^9 CFU/day.
  • Both pivotal RCTs used a 1:1:1 mixture of CECT 7527, CECT 7528, and CECT 7529.
  • Korean products such as Superbiotics Cholesterol are distributed, but CFU count, storage, viable count near expiry, and added ingredients should be checked.
  • The Korean regulator advises caution for disease or medication use, allergic conditions or short-bowel syndrome, infants and children, and pregnancy or lactation.
Gap Measurement · Verdict 416 · C 57
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 60-person, 12-week Fuentes 2013 RCT reported a 13.6% total-cholesterol reduction with AB-LIFE at 1.2×10^9 CFU/day and lower LDL in the high-baseline subgroup. AB-BIOTICS employees designed and analyzed the study, which received product-development funding. The 86-person German Müller 2025 RCT used the same strains and dose and found LDL changes of -6.6 mg/dL versus +2.3 mg/dL with placebo and a -10.4 mg/dL total-cholesterol change, but the effect was about 3% and responses varied widely.

02

Why this is classified as C (57)

Two trials of the same proprietary blend are positive and one is independently funded, but the later effect is small and differs greatly from the initial estimate, supporting C with 57 points for surrogate evidence.

Counterpoint. An adjunctive LDL and total-cholesterol signal remains for the three-strain combination at 1.2×10^9 CFU/day. This does not extend to the species as a whole or prevention of cardiovascular events.

Rejudgment record. New verdict — Positive lipid surrogates in 60-person and 86-person RCTs of the same three-strain blend, but early industry linkage, markedly different effect sizes, and proprietary attribution

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Fuentes MC et al. 2013Randomized double-blind placebo-controlled trial60Spanish product-development grants; conflicts involving AB-BIOTICS employeesTotal cholesterol, LDL-C, and oxidized LDL-CTotal cholesterol fell 13.6%; LDL-C fell 17.6% in the high-baseline subgroup.Key
Müller M et al. 2025Randomized double-blind placebo-controlled trial86German Research Foundation and Projekt DEALLDL-C, total cholesterol, triglycerides, and HDL-CLDL-C fell about 3.2% and total cholesterol about 3.3%; triglycerides, HDL-C, and the LDL/HDL ratio did not differ between groups.Key
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Fuentes MC, Lajo T, Carrión JM, Cuñé J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br J Nutr. 2013;109(10):1866-1872. PMID: 23017585. DOI: 10.1017/S000711451200373X.
checked
Müller M, Kerlikowsky F, Greupner T, Amend L, Strowig T, Hahn A. Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of Lactobacillus plantarum Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. Probiotics Antimicrob Proteins. 2025;17(3):1086-1095. DOI: 10.1007/s12602-023-10191-2.
checked
Ministry of Food and Drug Safety. AB-LIFE probiotic blend, individually recognized ingredient 2022-14. February 25, 2022. No PMID or DOI.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

AB-LIFE probiotic blend x improved LDL and total cholesterol Evidence Grade C card
[Chamgap] AB-LIFE probiotic blend x improved LDL and total cholesterol — Evidence Grade C·57. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/ab-life-probiotic-blend-ldl-total-cholesterol/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.